MRNA vs ZM
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 11, 2026
MRNA
ZM
Investment Advisor Scores
ZM
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | ZM | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 14.2653 | ZM |
| PEG Ratio | 0 | 2.3778 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 29.2% | 4.9% | MRNA |
| Earnings Growth | -85.1% | 342.3% | ZM |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 34.0/100 | 48.6/100 | ZM |
| Profit Margin | -110.5% | 65.2% | ZM |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | HOLD | ZM |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
MarkupPrice above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53
ZM
NeutralMixed signals - no dominant trend phase, RSI 56
Fundamentals Snapshot
| Metric | MRNA | ZM |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -53.3 | 27.5 |
| Trailing P/E | — | 8.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.3% | 0.0% |
| Gross Margin | -0.4% | 0.8% |
| Operating Margin | -0.8% | 0.2% |
| EPS | -6.98 | 11.63 |
| Dividend Yield | — | — |